Wired for What’s Next.
Reach your press release and disclosure targets.
Get more views with multimedia.
Track your results and refine your message.
Be the news everyone talks about.
Latest News
Today is September 20, 2020.
All times in Eastern Daylight Time.
-
リネージュ・ロジスティクス、事業成長の推進と技術・自動化への追加投資実現のため新規株式で16億ドルを調達
米ミシガン州ノバイ--(BUSINESS WIRE)--（ビジネスワイヤ） -- 世界最大で最も革新的な温度管理産業用REIT・物流ソリューション提供企業のリネージュ・ロジスティクス（「リネージュ」または「当社」）は本日、新規・既存の戦略的パートナーから株式で16億ドルを調達したと発表しました。参加した投資家は、オックスフォード・プロパティーズ・グループ（オックスフォード・プロパティーズ）、... more » -
TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Results from a prespecified exploratory analysis of the positive ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a clinically mea... more » -
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
PRINCETON, N.J., & ALAMEDA, Calif.--(BUSINESS WIRE)--Opdivo in Combination with CABOMETYX Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma.... more » -
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (ca... more »
-
ESMO 2020 : Cabometyx® (cabozantinib) en association avec Opdivo® (nivolumab) démontre des bénéfices significatifs en termes de survie chez les patients atteints d’un carcinome du rein avancé dans l’étude pivotale de Phase III CheckMate 9ER
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext : IPN ; ADR : IPSEY) a annoncé aujourd’hui la première présentation des résultats de l’étude pivotale de Phase III CheckMate 9ER dans laquel... more »
-
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
KENILWORTH, N.J., & BRUSSELS--(BUSINESS WIRE)--Merck’s KEYTRUDA Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma more » -
Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that it presented the latest results from three Phase III studies ... more » -
Resumen: BeiGene presenta datos en el ESMO Virtual Congress 2020 sobre el ensayo de fase 3 de tislelizumab en el tratamiento de primera línea del cáncer de pulmón de células no pequeñas y no escamosas y el ensayo de fase 2 de pamiparib...
CAMBRIDGE, Massachusetts & PEKÍN--(BUSINESS WIRE)-- BeiGene presenta datos en el ESMO Virtual Congress 2020 sobre el ensayo de fase 3 de tislelizumab en el tratamiento de primera línea del cáncer ... more » -
Samenvatting: BeiGene presenteert gegevens op ESMO Virtual Congress 2020 over fase 3-onderzoek met tislelizumab bij eerstelijns niet-plaveiselcel niet-kleincellige longkanker en fase 2-onderzoek met pamiparib bij gevorderde eierstokkanker
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), een commercieel biotechnologiebedrijf gericht op de ontwikkeling en commercialisering van innovatieve geneesm... more »
-
BeiGene präsentiert auf dem ESMO Virtual Congress 2020 Ergebnisse der Phase-3-Studie zu Tislelizumab als Erstlinientherapie beim Nicht-Plattenepithel-, nicht-kleinzelligen Lungenkrebs und der Phase-2-Studie zu Pamiparib beim fortgeschrittenen...
CAMBRIDGE, Massachusetts, und PEKING--(BUSINESS WIRE)-- BeiGene präsentiert auf dem ESMO Virtual Congress 2020 Ergebnisse der Phase-3-Studie zu Tislelizumab als Erstlinientherapie beim Nicht-Platt... more »
-
Takeda präsentiert neue Daten zu wissenschaftlichen Fortschritten bei Lungenkrebs auf dem virtuellen ESMO-Kongress
CAMBRIDGE (Mass./USA) und OSAKA (Japan)--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) („Takeda“) gab heute bekannt, dass das Unternehmen auf dem virtuellen Kongress ... more » -
Halo Provides an Update on Bophelo Bioscience
TORONTO--(BUSINESS WIRE)--Halo Labs Inc. (“Halo” or the “Company”) is pleased to provide an update in respect of recent developments for Bophelo Bioscience & Wellness (Pty) Ltd. (“Bophelo”) in ... more » -
COVID-19 Recovery Analysis: HVDC Converter Stations Market | Increase in Global Power Demand to Boost Market Growth | Technavio
LONDON--(BUSINESS WIRE)--The Global HVDC Converter Stations Market will grow by $ 3.36 bn during 2020-2024 more » -
Horizontal Carousel Market: COVID-19 Business Continuity Plan | Evolving Opportunities with Bastian Solutions LLC and Conveyors & Drives Inc. | Technavio
LONDON--(BUSINESS WIRE)--The Global Horizontal Carousel Market will grow by $ 63.78 mn during 2020-2024 more » -
LAS VEGAS SANDS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Las Vegas Sands Corp. - LVS
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an ... more »